ICON9
21 Dec 2020
Trial Summary
ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
Acronym:
ICON9
ACTRN/NCT /ethics:
NCT03278717
Scientific title:
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients
Sponsor / Cooperative group:
University College, London
Trial & Patient Characteristics
| Cancer Type | Gynaecological |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Female |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2018-06-15 |
| Anticipated End Date | 2023-12-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruiting |